{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:53:21Z","timestamp":1791996801491,"version":"4.4.0"},"reference-count":40,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Several cutaneous manifestations in patients undergoing COVID-19 vaccination have been described in the literature. Herein, we presented a case of new-onset vitiligo that occurred after the second dose of the Comirnaty vaccine. An updated literature search revealed the occurrence of a total of 16 cases, including new-onset or worsening of preexisting vitiligo. Given the autoimmune pathogenesis of the disease, we reviewed and discussed the potential role of the vaccine prophylaxis as a trigger for the development of such hypopigmented skin lesions.<\/jats:p>","DOI":"10.3390\/vaccines10101647","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T06:13:27Z","timestamp":1665468807000},"page":"1647","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Vitiligo-like Lesions and COVID-19: Case Report and Review of Vaccination- and Infection-Associated Vitiligo"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6470-8751","authenticated-orcid":false,"given":"Laura","family":"Macca","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, Messina, Italy C\/O A.O.U.P. \u201cGaetano Martino\u201d, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-3279","authenticated-orcid":false,"given":"Lucia","family":"Peterle","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, Messina, Italy C\/O A.O.U.P. \u201cGaetano Martino\u201d, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5987-3576","authenticated-orcid":false,"given":"Manuela","family":"Ceccarelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Catania, Catania, Italy C\/O ARNAS \u201cGaribaldi\u201d, \u201cNesima\u201d Hospital, Via Palermo 636, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ylenia","family":"Ingrasciotta","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Pharmacology, University of Messina, Messina, Italy C\/O A.O.U.P. \u201cGaetano Martino\u201d, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8113-8452","authenticated-orcid":false,"given":"Giuseppe","family":"Nunnari","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Messina, Messina, Italy C\/O A.O.U.P. \u201cGaetano Martino\u201d, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-8779","authenticated-orcid":false,"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Dermatology, University of Messina, Messina, Italy C\/O A.O.U.P. \u201cGaetano Martino\u201d, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e15196","DOI":"10.1111\/dth.15196","article-title":"Sudden Onset of Vitiligo after COVID-19 Vaccine","volume":"35","author":"Ciccarese","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous Reactions Reported after Moderna and Pfizer COVID-19 Vaccination: A Registry-Based Study of 414 Cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.jaad.2021.01.023","article-title":"The Clinical Spectrum of COVID-19\u2013Associated Cutaneous Manifestations: An Italian Multicenter Study of 200 Adult Patients","volume":"84","author":"Marzano","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1111\/jdv.16669","article-title":"Diversity of Clinical Ap-pearance of Cutaneous Manifestations in the Course of COVID-19","volume":"34","author":"Guarneri","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/ced.14842","article-title":"Vitiligo in a COVID-19-vaccinated Patient with Ulcerative Colitis: Coincidence?","volume":"47","author":"Aktas","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e04865","DOI":"10.1002\/ccr3.4865","article-title":"New-onset Vitiligo Following MRNA-1273 (Moderna) COVID-19 Vaccination","volume":"9","author":"Kaminetsky","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1002\/ski2.86","article-title":"New-onset Vitiligo Following COVID-19 Disease","volume":"2","author":"Herzum","year":"2022","journal-title":"Ski. Health Dis."},{"key":"ref_8","first-page":"e15502","article-title":"COVID-19 and Autoimmune Phenomena: Vitiligo after Astrazeneca Vaccine","volume":"35","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"T721","DOI":"10.1016\/j.ad.2022.06.012","article-title":"Facial Vitiligo After SARS-CoV-2 Vaccination","volume":"113","year":"2022","journal-title":"Actas Dermosifiliogr."},{"key":"ref_10","first-page":"e20902","article-title":"Vitiligo Possibly Triggered by COVID-19 Vaccination","volume":"14","author":"Militello","year":"2022","journal-title":"Cureus"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nicolaidou, E., Vavouli, C.H., Koumprentziotis, I.A., Gerochristou, M., and Stratigos, A. (J. Eur. Acad. Dermatol. Venereol., 2022). New-onset Vitiligo after COVID-19 mRNA Vaccination: A Causal Association?, J. Eur. Acad. Dermatol. Venereol., online ahead of print.","DOI":"10.1111\/jdv.18513"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Singh, R., Cohen, J.L., Astudillo, M., Harris, J.E., and Freeman, E.E. (JAAD Case Rep., 2022). Vitiligo of the Arm after COVID-19 Vaccination, JAAD Case Rep., online ahead of print.","DOI":"10.1016\/j.jdcr.2022.06.003"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jdcr.2022.01.030","article-title":"Vitiligo Following COVID-19: A Case Report and Review of Pathophysiology","volume":"22","author":"Schmidt","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jdcr.2022.02.021","article-title":"New-Onset of Vitiligo in a Child Following COVID-19 Vaccination","volume":"22","author":"Bukhari","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/jocd.14843","article-title":"Newly-developed Vitiligo Following COVID-19 MRNA Vaccine","volume":"21","author":"Sivaz","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/jocd.14677","article-title":"A New-onset Vitiligo Following the Inactivated COVID-19 Vaccine","volume":"21","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_17","first-page":"e15422","article-title":"Lichen Planus and Vitiligo Occurring after ChAdOx1 NCoV-19 Vaccination against SARS-CoV-2","volume":"35","author":"Gamonal","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e15434","DOI":"10.1111\/dth.15434","article-title":"Vitiligo Worsened Following the Second Dose of mRNA SARS-CoV-2 Vaccine","volume":"35","author":"Caroppo","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e15280","DOI":"10.1111\/dth.15280","article-title":"Worsening of the Vitiligo Following the Second Dose of the BNT162B2 MRNA COVID-19 Vaccine","volume":"35","author":"Okan","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9142","DOI":"10.4081\/dr.2021.9142","article-title":"Vitiligo: What\u2019s Old, What\u2019s New","volume":"13","author":"Bertolani","year":"2021","journal-title":"Dermatol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","article-title":"A Review of the Worldwide Prevalence of Vitiligo in Children\/Adolescents and Adults","volume":"51","author":"Schallreuter","year":"2012","journal-title":"Int. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/1573396316666201210125858","article-title":"Vitiligo: An Updated Narrative Review","volume":"17","author":"Leung","year":"2021","journal-title":"Curr. Pediatr. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.autrev.2015.12.006","article-title":"Vitiligo: Pathogenesis, Clinical Variants and Treatment Approaches","volume":"15","author":"Iannella","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/pcmr.12208","article-title":"Preferential Secretion of Inducible HSP70 by Vitiligo Melanocytes under Stress","volume":"27","author":"Mosenson","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.12659\/MSM.914898","article-title":"Perspectives of New Advances in the Pathogenesis of Vitiligo: From Oxidative Stress to Autoimmunity","volume":"25","author":"Wang","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/pcmr.12949","article-title":"An Update on Vitiligo Pathogenesis","volume":"34","author":"Seneschal","year":"2021","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/1346-8138.15743","article-title":"Vitiligo: A Focus on Pathogenesis and Its Therapeutic Implications","volume":"48","author":"Bergqvist","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3","volume":"138","author":"Boniface","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/14787210.2021.1863146","article-title":"An Update on COVID-19 Pandemic: The Epidemiology, Pathogenesis, Prevention and Treatment Strategies","volume":"19","author":"Tsang","year":"2021","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100073","DOI":"10.1016\/j.sintl.2020.100073","article-title":"Update Vision on COVID-19: Structure, Immune Pathogenesis, Treatment and Safety Assessment","volume":"2","author":"Agrahari","year":"2021","journal-title":"Sens. Int."},{"key":"ref_31","unstructured":"(2022, January 31). WHO Coronavirus (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e770","DOI":"10.1111\/jdv.16841","article-title":"Management of Biological Therapies for Chronic Plaque Psoriasis during COVID-19 Emergency in Italy","volume":"34","author":"Talamonti","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"20178","DOI":"10.1038\/s41598-020-77194-9","article-title":"Ocular Surface Manifestation of COVID-19 and Tear Film Analysis","volume":"10","author":"Meduri","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/pcmr.12219","article-title":"Type I Interferon Signature in the Initiation of the Immune Response in Vitiligo","volume":"27","author":"Bertolotti","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Sa Ribero, M., Jouvenet, N., Dreux, M., and Nisole, S. (2020). Interplay between SARS-CoV-2 and the Type I Interferon Response. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008737"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.clindermatol.2021.07.011","article-title":"The Histologic and Molecular Correlates of COVID-19 Vaccine-Induced Changes in the Skin","volume":"39","author":"Magro","year":"2021","journal-title":"Clin. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/ced.14895","article-title":"De Novo Generalized Pustular Psoriasis Following Oxford-AstraZeneca COVID-19 Vaccine","volume":"47","author":"Elamin","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/ced.14941","article-title":"Comment on \u2018De Novo Generalized Pustular Psoriasis Following Oxford-AstraZeneca COVID-19 Vaccine\u2019: Possible Role for Type I Interferons","volume":"47","author":"Awada","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Motolese, A., Ceccarelli, M., Macca, L., Li Pomi, F., Ingrasciotta, Y., Nunnari, G., and Guarneri, C. (2022). Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020228"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s13555-020-00475-8","article-title":"Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations","volume":"11","author":"Gisondi","year":"2021","journal-title":"Dermatol. Ther."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/10\/1647\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:44:53Z","timestamp":1760143493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/10\/1647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["vaccines10101647"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10101647","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}